AMP award given to Dr. Brian Druker
Posted 20 December 2015 - 10:01 PM
The Association for Molecular Pathology is honoring Dr. Brian Druker. The citation reads:
Brian J. Druker, MD, Director, Knight Cancer Institute, Oregon Health & Science University, will receive the AMP Award for Excellence in Molecular Diagnostics. The award recognizes lifetime, pioneering, and special achievements by professionals in the field. "This award is the highest honor bestowed by the Association," said Janina A. Longtine, MD, AMP President, "Witnessing the effects of chemotherapy or bone marrow transplanation on patients drove Dr. Druker to lead the development and clinical trials of the drug imatinib (Gleevec) for chronic myelogenous leukemia (CML). Gleevec was the first of its kind developed to fight cancer by targeting mutated cells, leaving healthy cells alone and causing only minimal side effects, said Longtine. Dr. Drucker is the 17th recipient of this prestigious award.
You can read the news release here: http://www.newswise....ward-recipients
Diagnosed in February 2014. Started Imatinib 400 in April.
2014: 3.18 0.91
2015: 0.22 0.16 0.04 0.55
2016: 0.71 0.66
(Started Imatinib 600 in April 2016)
2016: 0.42 0.13 0.45
2017: 0.17 0.06 0.10 0.06 0.34
Posted 21 December 2015 - 06:48 AM
Thanks for posting this, Dom. I had not seen it.
"You can't change the direction of the wind but you can adjust your sails."
DX 12/08; Gleevec 400mg; liver toxicity; Sprycel 100mg.; CCyR 4/10; MMR 8/10; Pleural Effusion 2/12; Sprycel 50mg. Maintaining MMR; 2/15 PCRU; 8/16 drifting in and out of undetected like a wave meeting the shore. Retired 12/23/2016! 18 months of PCRU, most recent at Mayo on 7/25/17 was negative at their new sensitivity reporting of 0.003.<p>
Posted 30 December 2015 - 08:39 PM
Happy New Year to all.
1 user(s) are reading this topic
0 members, 1 guests, 0 anonymous users